Role of Galectin-3 in Diagnosis and Severity Assessment of Epicardial Artery Lesions in Patients with Suspected Coronary Artery Disease

Overview

Journal BMC Cardiovasc Disord

Publisher Biomed Central

Specialty Cardiology & Vascular Diseases

Date 2023 May 23

PMID 37221462

Authors

Ivica Bosnjak

Drazen Bedekovic

Kristina Selthofer-Relatic

Hrvoje Roguljic

Ivica Mihaljevic

Ines Bilic-Curcic

Affiliations

Soon will be listed here.

Abstract

Background: This study aimed to investigate the possible role of serum galectin-3 (Gal-3) levels in the diagnosis and assessment of significant epicardial artery lesions in patients with suspected coronary artery disease (CAD).

Methods: This was a single-center cross sectional cohort study including 168 subjects with suspected CAD and indications for coronary angiography divided into three groups: percutaneous coronary intervention (PCI) group (N 64), coronary artery bypass graft surgery (CABG) group (N 57), and group with no coronary stenosis (N 47). Gal-3 levels were measured and the syntax score (Ss) was calculated.

Results: The mean value of Gal-3 in the PCI and CABG group was 19.98 ng/ml, while in the control group, it was 9.51 ng/ml (p < 0.001). The highest value of Gal-3 was found in the group of subjects with three-vessel disease (p < 0.001). When subgroups were analyzed by Gal-3 levels (< 17.8 ng/ml low, 18.8-25.9 ng/ml intermediate, > 25 ng/ml high risk) there was a significant difference between at least two Gal-3 groups for the arithmetic mean of Syntax score (p < 0.001). The syntax I's arithmetic mean at low and intermediate-risk Gal-3 levels was significantly lower than at high-risk Gal-3 levels (p < 0.001).

Conclusion: Gal-3 could be used as an additional tool for diagnosis and severity assessment of atherosclerotic disease in patients with suspected CAD. Furthermore, it could help identify high-risk subjects in patients with stable CAD.

Citing Articles

Heart failure biomarkers in revascularized patients with stable coronary heart disease as clinical outcome predictors.

Bosnjak I, Bedekovic D, Selthofer-Relatic K, Roguljic H, Mihaljevic I, Dukic D Front Cardiovasc Med. 2024; 11:1458120.

PMID: 39346100 PMC: 11428046. DOI: 10.3389/fcvm.2024.1458120.

Associations of galectin-3 levels with measures of vascular disease in patients with rheumatoid arthritis.

Nussdorf A, Park E, Amigues I, Geraldino-Pardilla L, Bokhari S, Giles J Semin Arthritis Rheum. 2024; 65:152357.

PMID: 38244444 PMC: 11238268. DOI: 10.1016/j.semarthrit.2023.152357.

References

Ong A, Serruys P, Mohr F, Morice M, Kappetein A, Holmes Jr D . The SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: design, rationale, and run-in phase. Am Heart J. 2006; 151(6):1194-204. DOI: 10.1016/j.ahj.2005.07.017. View

Lisowska A, Knapp M, Tycinska A, Motybel E, Kaminski K, Swiecki P . Predictive value of Galectin-3 for the occurrence of coronary artery disease and prognosis after myocardial infarction and its association with carotid IMT values in these patients: A mid-term prospective cohort study. Atherosclerosis. 2016; 246:309-17. DOI: 10.1016/j.atherosclerosis.2016.01.022. View

Sanchez-Mas J, Lax A, Asensio-Lopez M, Palacio M, Caballero L, Garrido I . Galectin-3 expression in cardiac remodeling after myocardial infarction. Int J Cardiol. 2014; 172(1):e98-e101. DOI: 10.1016/j.ijcard.2013.12.129. View

Li M, Guo K, Huang X, Feng L, Yuan Y, Li J . Association Between Serum Galectin-3 Levels and Coronary Stenosis Severity in Patients With Coronary Artery Disease. Front Cardiovasc Med. 2022; 9:818162. PMC: 8858949. DOI: 10.3389/fcvm.2022.818162. View

Hogas S, Bilha S, Branisteanu D, Hogas M, Gaipov A, Kanbay M . Potential novel biomarkers of cardiovascular dysfunction and disease: cardiotrophin-1, adipokines and galectin-3. Arch Med Sci. 2017; 13(4):897-913. PMC: 5507105. DOI: 10.5114/aoms.2016.58664. View

Tsai T, Sung P, Chang L, Sun C, Yeh K, Chung S . Value and level of galectin-3 in acute myocardial infarction patients undergoing primary percutaneous coronary intervention. J Atheroscler Thromb. 2012; 19(12):1073-82. DOI: 10.5551/jat.12856. View

Oyenuga A, Folsom A, Fashanu O, Aguilar D, Ballantyne C . Plasma Galectin-3 and Sonographic Measures of Carotid Atherosclerosis in the Atherosclerosis Risk in Communities Study. Angiology. 2018; 70(1):47-55. PMC: 6239970. DOI: 10.1177/0003319718780772. View

Aksan G, Gedikli O, Keskin K, Nar G, Inci S, Yildiz S . Is galectin-3 a biomarker, a player-or both-in the presence of coronary atherosclerosis?. J Investig Med. 2016; 64(3):764-70. DOI: 10.1136/jim-2015-000041. View

Bosnjak I, Selthofer-Relatic K, Vcev A . Prognostic value of galectin-3 in patients with heart failure. Dis Markers. 2015; 2015:690205. PMC: 4415488. DOI: 10.1155/2015/690205. View

10.

Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, DAngelo A, Schirinzi S . Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol. 2012; 24(4):905-13. DOI: 10.1177/039463201102400409. View

11.

Kusaka H, Yamamoto E, Hirata Y, Fujisue K, Tokitsu T, Sugamura K . Clinical significance of plasma galectin-3 in patients with coronary artery disease. Int J Cardiol. 2015; 201:532-4. DOI: 10.1016/j.ijcard.2015.08.099. View

12.

Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C . 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2019; 41(3):407-477. DOI: 10.1093/eurheartj/ehz425. View

13.

Dumic J, Dabelic S, Flogel M . Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760(4):616-35. DOI: 10.1016/j.bbagen.2005.12.020. View

14.

Robbins C, Hilgendorf I, Weber G, Theurl I, Iwamoto Y, Figueiredo J . Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013; 19(9):1166-72. PMC: 3769444. DOI: 10.1038/nm.3258. View

15.

Sun R, Lu L, Liu M, Cao Y, Li X, Liu H . Biomarkers and heart disease. Eur Rev Med Pharmacol Sci. 2014; 18(19):2927-35. View

16.

Turan Y, Demir V . The relation of endocan and galectin-3 with ST-segment resolution in patients with ST-segment elevation myocardial infarction. Adv Clin Exp Med. 2020; 29(4):453-458. DOI: 10.17219/acem/118126. View

17.

Dickstein K, Cohen-Solal A, Filippatos G, McMurray J, Ponikowski P, Poole-Wilson P . ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the.... Eur J Heart Fail. 2008; 10(10):933-89. DOI: 10.1016/j.ejheart.2008.08.005. View

18.

de Boer R, Voors A, Muntendam P, van Gilst W, Van Veldhuisen D . Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail. 2009; 11(9):811-7. DOI: 10.1093/eurjhf/hfp097. View